FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?

Cholangiocarcinomas (CCAs) are rare but aggressive tumours with poor diagnosis and limited treatment options. Molecular targeted therapies became a promising proposal for patients after progression under first-line chemical treatment. In light of an escalating prevalence of CCA, it is crucial to ful...

Descripción completa

Detalles Bibliográficos
Autores principales: Chmiel, Paulina, Gęca, Katarzyna, Rawicz-Pruszyński, Karol, Polkowski, Wojciech P., Skórzewska, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737583/
https://www.ncbi.nlm.nih.gov/pubmed/36497187
http://dx.doi.org/10.3390/cells11233929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737583/
https://www.ncbi.nlm.nih.gov/pubmed/36497187
http://dx.doi.org/10.3390/cells11233929

Ejemplares similares